WHIP 180

Drug Profile

WHIP 180

Alternative Names: WHI-P180

Latest Information Update: 24 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wayne Hughes Institute
  • Developer Transition Therapeutics; Wayne Hughes Institute
  • Class Antiallergics; Antihistamines
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic rhinitis; Brain cancer; Food hypersensitivity; Urticaria

Most Recent Events

  • 15 Mar 2006 Preclinical trials in Brain cancer in Canada (unspecified route)
  • 15 Sep 1998 Preclinical development for Allergic rhinitis in USA (Unknown route)
  • 15 Sep 1998 Preclinical development for Food allergy in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top